Abstract Background In 2010–2017, meningococcal serogroup A conjugate vaccine (MACV)
was introduced in 21 African meningitis belt countries. Neisseria meningitidis A epidemics …

Background A novel meningococcal serogroup A conjugate vaccine (MACV [MenAfriVac])
was developed as part of efforts to prevent frequent meningitis outbreaks in the African …

Abstract Background In 2010, Niger and other meningitis belt countries introduced a
meningococcal serogroup A conjugate vaccine (MACV). We describe the epidemiology of …

Summary Background To combat Neisseria meningitidis serogroup A epidemics in the
meningitis belt of sub-Saharan Africa, a meningococcal serogroup A conjugate vaccine …

Abstract Background During 2014, 4 regions in Togo within the African meningitis belt
implemented vaccination campaigns with meningococcal serogroup A conjugate vaccine …

Abstract In sub-Saharan Africa, bacterial meningitis remains a significant public health
problem, especially in the countries of the meningitis belt, where Neisseria meningitidis …

The introduction and rollout of a meningococcal serogroup A conjugate vaccine,
MenAfriVac, in the African meningitis belt has eliminated serogroup A meningococcal …

Background Since 2010, countries in the African meningitis belt have been introducing a
new serogroup A meningococcal conjugate vaccine (MenAfriVac®) through mass …

Background An affordable, highly immunogenic Neisseria meningitidis serogroup A
meningococcal conjugate vaccine (PsA–TT) was licensed for use in sub-Saharan Africa in …

For more than a century, meningitis epidemics have regularly recurred across sub-Saharan
Africa, involving 19 contiguous countries that constitute a 'meningitis belt'where historically …